Abstract 1123O
Background
In the first substudy of the Circulating Cell-free Genome Atlas (CCGA) study (NCT02889978; Sep 2016), cfDNA multi-omics were evaluated in prototype cfDNA-based MCED tests.
Methods
Plasma and matched white blood cells (WBCs) were collected and sequenced from CCGA participants. Where available, tumor biopsies were also sequenced. Six cfDNA-omics were used: whole-genome (WG) methylation data from WG bisulfite sequencing (30×); small somatic variant data from error-corrected targeted sequencing (TS; 60,000×); and somatic copy-number aberration (SCNA), fragment length, fragment endpoint, and allelic imbalance data from WG sequencing (WGS; 30×). Samples were split into independent training (T) and validation (V) sets and 10 classifiers were trained to detect solid cancer (carcinomas, sarcomas, lymphomas): 1 per -omic, 2 corrected for clonal hematopoiesis (CH) using germline DNA from paired WBC sequencing, 1 pan-omics, 1 clinical data only. These were assessed for cancer detection and clinical limit of detection (cLOD), which was estimated as the probability of detecting cancer as a function of circulating tumor fraction (cTF) using matched tumor biopsies. Three additional classifiers (each using WG methylation, TS, or SCNA) were trained to predict cancer signal origin (CSO) and were assessed for accuracy.
Results
Of 2,800 participants, 2,261 (1,414 T; 847 V) had analyzable results. T and V results were similar; all results here are for V. cTF accounted for >72% of the variance in cancer detection scores. The cLOD was >1.5-fold lower for WG methylation than any WGS or TS classifier (even with WBC CH correction for WGS/TS). CSO prediction was >1.8-fold more accurate using WG methylation than TS or SCNA.
Conclusions
The strong correlation between cTF and cancer detection performance suggests that cLOD may be an attractive metric for comparing MCED test performance at equal specificity. Here, a WG methylation assay outperformed WGS or TS without needing additional WBC sequencing for CH. These data informed the design of a significantly improved targeted methylation MCED test for further CCGA substudies to support clinical use.
Clinical trial identification
NCT02889978.
Editorial acknowledgement
Medical writing assistance was provided by Alexis Fedorchak (GRAIL, Inc.).
Legal entity responsible for the study
GRAIL, Inc.
Funding
GRAIL, Inc.
Disclosure
M.C. Liu: Financial Interests, Institutional, Advisory Board, The Mayo Clinic was compensated for MCL’s and DDT’s, advisory board activities for GRAIL, Inc. A. Jamshidi: Financial Interests, Personal, Full or part-time Employment: GRAIL, Inc.; Financial Interests, Personal, Stocks/Shares: GRAIL, Inc.; Financial Interests, Personal, Stocks/Shares: Illumina, Inc. E.A. Klein: Financial Interests, Personal, Advisory Role: GRAIL, Inc.; Financial Interests, Personal, Advisory Role: Genomic Health; Financial Interests, Personal, Advisory Role: Genome Dx. O. Venn, E. Hubbell, J.F. Beausang, N. Zhang: Financial Interests, Personal, Full or part-time Employment: GRAIL, Inc.; Financial Interests, Personal, Stocks/Shares: GRAIL, Inc. K.N. Kurtzman, C. Hou: Financial Interests, Personal, Full or part-time Employment: GRAIL, Inc.; Financial Interests, Personal, Stocks/Shares: GRAIL, Inc.; Financial Interests, Personal, Stocks/Shares: Illumina, Inc. D.D. Thiel: Financial Interests, Institutional, Advisory Board, The Mayo Clinic was compensated for MCL’s and DDT’s, advisory board activities for GRAIL, Inc. A.H. Bryce: Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Merck; Financial Interests, Personal, Advisory Role: Bayer; Financial Interests, Personal, Advisory Role: Astellas Pharmaceuticals. M.V. Seiden: Financial Interests, Personal, Full or part-time Employment: McKesson Corporation; Financial Interests, Personal, Stocks/Shares: McKesson Corporation; Financial Interests, Personal, Advisory Role: GRAIL, Inc. C. Swanton: Financial Interests, Personal, Stocks/Shares: GRAIL, Inc; Financial Interests, Personal, Stocks/Shares: Epic Biociences; Financial Interests, Personal, Stocks/Shares: Apogen Biotech; Financial Interests, Personal and Institutional, Research Grant: Pfizer; Financial Interests, Personal and Institutional, Research Grant: AstraZeneca; Financial Interests, Personal, Advisory Role: Roche Ventana; Financial Interests, Personal, Advisory Role: Celgene; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Genentech; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal and Institutional, Member of the Board of Directors: Achilles Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
1757O - Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients
Presenter: Alexander Shoushtari
Session: Proffered Paper session - Translational research
Resources:
Abstract
Slides
Webcast
1758O - Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency
Presenter: Kaysia Ludford
Session: Proffered Paper session - Translational research
Resources:
Abstract
Slides
Webcast
1124O - Prediction of distant relapse in patients with invasive breast cancer from deep learning models applied to digital pathology slides
Presenter: Ingrid Garberis
Session: Proffered Paper session - Translational research
Resources:
Abstract
Slides
Webcast
Invited Discussant 1123O and 1757O
Presenter: Christian Rolfo
Session: Proffered Paper session - Translational research
Resources:
Webcast
Q&A and live discussion
Presenter: Christian Rolfo
Session: Proffered Paper session - Translational research
Resources:
Slides
Webcast
Invited Discussant 1758O and 1124O
Presenter: Sherene Loi
Session: Proffered Paper session - Translational research
Resources:
Webcast
Q&A and live discussion
Presenter: Sherene Loi
Session: Proffered Paper session - Translational research
Resources:
Slides
Webcast